These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 25003808)

  • 1. An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.
    Obici L; Merlini G
    Expert Opin Investig Drugs; 2014 Sep; 23(9):1239-51. PubMed ID: 25003808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent progress in the understanding and treatment of transthyretin amyloidosis.
    Sekijima Y
    J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
    Sekijima Y
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Familial amyloid polyneuropathies: therapeutic issues].
    Adams D; Cauquil C; Théaudin M
    Bull Acad Natl Med; 2012 Oct; 196(7):1333-45; discussion 1345-7. PubMed ID: 23815018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TTR kinetic stabilizers and TTR gene silencing: a new era in therapy for familial amyloidotic polyneuropathies.
    Adams D; Cauquil C; Labeyrie C; Beaudonnet G; Algalarrondo V; Théaudin M
    Expert Opin Pharmacother; 2016; 17(6):791-802. PubMed ID: 26800456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
    Buxbaum JN
    Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recent Advances in Oligonucleotide-Based Therapy for Transthyretin Amyloidosis: Clinical Impact and Future Prospects.
    Hayashi Y; Jono H
    Biol Pharm Bull; 2018; 41(12):1737-1744. PubMed ID: 30504675
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tafamidis for transthyretin amyloidosis.
    de Lartigue J
    Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
    Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
    Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current and future treatment of amyloid neuropathies.
    Adams D; Cauquil C; Theaudin M; Rousseau A; Algalarrondo V; Slama MS
    Expert Rev Neurother; 2014 Dec; 14(12):1437-51. PubMed ID: 25416603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs.
    Castaño A; Drachman BM; Judge D; Maurer MS
    Heart Fail Rev; 2015 Mar; 20(2):163-78. PubMed ID: 25408161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological study.
    Planté-Bordeneuve V; Gorram F; Salhi H; Nordine T; Ayache SS; Le Corvoisier P; Azoulay D; Feray C; Damy T; Lefaucheur JP
    J Neurol; 2017 Feb; 264(2):268-276. PubMed ID: 27878441
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenesis of and therapeutic strategies to ameliorate the transthyretin amyloidoses.
    Sekijima Y; Kelly JW; Ikeda S
    Curr Pharm Des; 2008; 14(30):3219-30. PubMed ID: 19075702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging therapies in transthyretin amyloidosis - a new wave of hope after years of stagnancy?
    Müller ML; Butler J; Heidecker B
    Eur J Heart Fail; 2020 Jan; 22(1):39-53. PubMed ID: 31912620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides.
    Benson MD; Kluve-Beckerman B; Zeldenrust SR; Siesky AM; Bodenmiller DM; Showalter AD; Sloop KW
    Muscle Nerve; 2006 May; 33(5):609-18. PubMed ID: 16421881
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evolving landscape in the management of transthyretin amyloidosis.
    Hawkins PN; Ando Y; Dispenzeri A; Gonzalez-Duarte A; Adams D; Suhr OB
    Ann Med; 2015; 47(8):625-38. PubMed ID: 26611723
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis.
    Gertz MA; Scheinberg M; Waddington-Cruz M; Heitner SB; Karam C; Drachman B; Khella S; Whelan C; Obici L
    Expert Rev Clin Pharmacol; 2019 Aug; 12(8):701-711. PubMed ID: 31268366
    [No Abstract]   [Full Text] [Related]  

  • 19. [Transthyretin-related amyloidotic cardiomyopathy: looking for the etiological treatment].
    Longhi S; Gagliardi C; Milandri A; Manuzzi L; Rapezzi C
    G Ital Cardiol (Rome); 2014 May; 15(5):293-300. PubMed ID: 25002169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Newly developed drug therapies for familial amyloid polyneuropathy: diflunisal and tafamidis].
    Sekijima Y
    Brain Nerve; 2014 Jul; 66(7):773-81. PubMed ID: 24998822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.